Literature DB >> 17974982

Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.

Charles N Landen1, Yvonne G Lin, Guillermo N Armaiz Pena, Pamela D Das, Jesusa M Arevalo, Aparna A Kamat, Liz Y Han, Nicholas B Jennings, Whitney A Spannuth, Premal H Thaker, Susan K Lutgendorf, Cherylyn A Savary, Angela M Sanguino, Gabriel Lopez-Berestein, Steve W Cole, Anil K Sood.   

Abstract

There is growing evidence that chronic stress and other behavioral conditions are associated with cancer pathogenesis and progression, but the mechanisms involved in this association are poorly understood. We examined the effects of two mediators of stress, norepinephrine and epinephrine, on the activation of signal transducer and activator of transcription-3 (STAT3), a transcription factor that contributes to many promalignant pathways. Exposure of ovarian cancer cell lines to increasing concentrations of norepinephrine or epinephrine showed that both independently increased levels of phosphorylated STAT3 in a dose-dependent fashion. Immunolocalization and ELISA of nuclear extracts confirmed increased nuclear STAT3 in response to norepinephrine. Activation of STAT3 was inhibited by blockade of the beta1- and beta2-adrenergic receptors with propranolol, and by blocking protein kinase A with KT5720, but not with the alpha receptor blockers prazosin (alpha1) and/or yohimbine (alpha2). Catecholamine-mediated STAT3 activation was not inhibited by pretreatment with an anti-interleukin 6 (IL-6) antibody or with small interfering RNA (siRNA)-mediated decrease in IL-6 or gp130. Regarding the effects of STAT3 activation, exposure to norepinephrine resulted in an increase in invasion and matrix metalloproteinase (MMP-2 and MMP-9) production. These effects were completely blocked by STAT3-targeting siRNA. In mice, treatment with liposome-incorporated siRNA directed against STAT3 significantly reduced isoproterenol-stimulated tumor growth. These studies show IL-6-independent activation of STAT3 by norepinephrine and epinephrine, proceeding through the beta1/beta2-adrenergic receptors and protein kinase A, resulting in increased matrix metalloproteinase production, invasion, and in vivo tumor growth, which can be ameliorated by the down-regulation of STAT3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17974982     DOI: 10.1158/0008-5472.CAN-07-0858

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

1.  Chronic exposure to stress hormones promotes transformation and tumorigenicity of 3T3 mouse fibroblasts.

Authors:  Melanie S Flint; Andrew Baum; Britteny Episcopo; Kelly Z Knickelbein; Angela J Liegey Dougall; William H Chambers; Frank J Jenkins
Journal:  Stress       Date:  2012-05-16       Impact factor: 3.493

Review 2.  Neuroendocrine influences on cancer progression.

Authors:  Guillermo N Armaiz-Pena; Steve W Cole; Susan K Lutgendorf; Anil K Sood
Journal:  Brain Behav Immun       Date:  2012-06-21       Impact factor: 7.217

Review 3.  Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma.

Authors:  Mian M K Shahzad; Yong-Hyun Shin; Koji Matsuo; Chunhua Lu; Masato Nishimura; De-Yo Shen; Yu Kang; Wei Hu; Edna M Mora; Cristian Rodriguez-Aguayo; Arvinder Kapur; Justin Bottsford-Miller; Gabriel Lopez-Berestein; Aleksandar Rajkovic; Anil K Sood
Journal:  Cancer Lett       Date:  2012-07-07       Impact factor: 8.679

Review 4.  Host factors and cancer progression: biobehavioral signaling pathways and interventions.

Authors:  Susan K Lutgendorf; Anil K Sood; Michael H Antoni
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

Review 5.  Sympathetic nervous system regulation of the tumour microenvironment.

Authors:  Steven W Cole; Archana S Nagaraja; Susan K Lutgendorf; Paige A Green; Anil K Sood
Journal:  Nat Rev Cancer       Date:  2015-09       Impact factor: 60.716

6.  Beta-adrenergic blocking drugs in breast cancer: a perspective review.

Authors:  Thomas I Barron; Linda Sharp; Kala Visvanathan
Journal:  Ther Adv Med Oncol       Date:  2012-05       Impact factor: 8.168

Review 7.  Biobehavioral influences on cancer progression.

Authors:  Erin S Costanzo; Anil K Sood; Susan K Lutgendorf
Journal:  Immunol Allergy Clin North Am       Date:  2011-02       Impact factor: 3.479

8.  Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors.

Authors:  Shipra Gandhi; Manu Pandey; Nischala Ammannagari; Chong Wang; Mark J Bucsek; Lamya Hamad; Elizabeth Repasky; Marc S Ernstoff
Journal:  Immunotherapy       Date:  2020-02-17       Impact factor: 4.196

9.  Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.

Authors:  Galina Gritsina; Fang Xiao; Shane W O'Brien; Rashid Gabbasov; Marisa A Maglaty; Ren-Huan Xu; Roshan J Thapa; Yan Zhou; Emmanuelle Nicolas; Samuel Litwin; Siddharth Balachandran; Luis J Sigal; Dennis Huszar; Denise C Connolly
Journal:  Mol Cancer Ther       Date:  2015-02-02       Impact factor: 6.261

10.  SubpathwayMiner: a software package for flexible identification of pathways.

Authors:  Chunquan Li; Xia Li; Yingbo Miao; Qianghu Wang; Wei Jiang; Chun Xu; Jing Li; Junwei Han; Fan Zhang; Binsheng Gong; Liangde Xu
Journal:  Nucleic Acids Res       Date:  2009-08-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.